Changing paradigms in intermediate-risk cervical cancer: Sedlis revisited
- PMID: 34454679
- DOI: 10.1016/j.ygyno.2021.08.004
Changing paradigms in intermediate-risk cervical cancer: Sedlis revisited
Conflict of interest statement
Declaration of Competing Interest Ritu Salani reports advisory board participation for GSK, Merck, Instil Bio, Seagen, and Arcus Biologics outside the submitted work. Puja Venkat reports no competing interests. Both authors were involved in the conception, design, review and editing of the manuscript.
Comment on
-
Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.Gynecol Oncol. 2021 Sep;162(3):532-538. doi: 10.1016/j.ygyno.2021.06.017. Epub 2021 Jul 1. Gynecol Oncol. 2021. PMID: 34217544 Free PMC article.
